Zydus Lifesciences rises on inking pact with Myriad Genetics
The company will exclusively market, create awareness, access and engage clinicians on three of Myriad Genetics’ broadly validated diagnostic platforms
Zydus Lifesciences is currently trading at Rs. 914.90, up by 1.05 points or 0.11% from its previous closing of Rs. 913.85 on the BSE.
The scrip opened at Rs. 914.00 and has touched a high and low of Rs. 929.75 and Rs. 911.40 respectively. So far 22967 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1059.00 on 19-Sep-2025 and a 52 week low of Rs. 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 931.55 and Rs. 909.50 respectively. The current market cap of the company is Rs. 92070.41 crore.
The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.20% and 6.80% respectively.
Zydus Lifesciences has signed an agreement with Myriad Genetics, a leader in molecular diagnostic testing and precision medicine company. With this, the company will be introducing MyRisk Hereditary Cancer Test, MyChoice HRD Plus, Homologous Recombination Deficiency (HRD) Test and Prolaris Prostate Cancer Prognostic Test to patients, clinicians, and healthcare systems across India. The MyRisk Test can help people safeguard their health and take precautionary steps and lifestyle changes that can minimise the risk of cancer. In patients suffering from prostate and ovarian cancers, the Prolaris Test and MyChoice HRD Plus Test, respectively, can help patients understand the disease progression and inform the right treatment path.
As part of this agreement, the company will exclusively market, create awareness, access and engage clinicians on three of Myriad Genetics’ broadly validated diagnostic platforms, MyRisk Hereditary Cancer Test, MyChoice HRD Plus Test for ovarian cancer, and Prolaris a gene expression Prostate Cancer Prognostic Test.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
